Body Shortcuts

R&D

A global pioneer in the development of new drugs

Research Areas

SK Biopharmaceuticals is pursuing the development of new, next-generation drugs with the goal of bringing safe and effective products to market to treat central nervous system (CNS) disorders. One of our core competencies is the ability to design drugs that can penetrate the blood-brain barrier*. Based on this capability, we have established a differentiated research pipeline for CNS disorders including both neurological and psychiatric disorders, and a chemical library of diverse compounds targeting CNS disorders. Also, we are focusing on the development of drugs for treatment of brain tumors. For this purpose, we are concentrating on the development of concurrently administered therapeutic drugs that can maximize the efficacy of targeted treatment drugs along with the treatment of the immune checkpoint inhibitor, utilizing a highly efficient screening (High Content Screening) system and cell strains and animal models in which the characteristics of patients have been reflected.
*Blood-brain barrier: the membrane that prevents penetration of specific substances from blood vessels into cerebral nerve tissues.